Norifumi Shioda Selected Research

N-Methylaspartate (NMDA)

1/2011	[Functional roles of constitutively active calcineurin in delayed neuronal death after brain ischemia].
10/2009	Generation and characterization of conditional heparin-binding EGF-like growth factor knockout mice.
2/2007	Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Norifumi Shioda Research Topics

Disease

10	Brain Ischemia (Cerebral Ischemia) 10/2015 - 07/2006
10	Ischemia 10/2015 - 01/2006
9	Hypertrophy 01/2014 - 12/2007
5	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2021 - 06/2011
5	ATR-X syndrome 10/2020 - 06/2011
5	Cognitive Dysfunction 10/2020 - 04/2011
5	Alzheimer Disease (Alzheimer's Disease) 02/2019 - 02/2007
5	Cardiomegaly (Heart Hypertrophy) 01/2014 - 01/2009
4	Memory Disorders (Memory Loss) 10/2015 - 07/2008
3	Intellectual Disability (Idiocy) 01/2022 - 01/2011
3	X-Linked Mental Retardation (Mental Retardation, X Linked) 01/2016 - 01/2011
3	Thalassemia 01/2016 - 01/2011
3	Myocardial Infarction 11/2010 - 01/2008
3	Myocardial Ischemia (Ischemic Heart Diseases) 10/2008 - 10/2007
2	Neoplasms (Cancer) 12/2022 - 01/2019
2	Infections 04/2022 - 03/2020
2	COVID-19 04/2022 - 01/2022
2	Synucleinopathies 08/2020 - 03/2020
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2014 - 01/2014
2	Body Weight (Weight, Body) 12/2011 - 12/2007
2	Catalepsy 04/2011 - 02/2010
2	Schizophrenia (Dementia Praecox) 04/2011 - 10/2009
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2011 - 07/2006
2	Mental Disorders (Mental Disorder) 01/2010 - 10/2009
2	Bipolar Disorder (Manic Depressive Psychosis) 10/2009 - 09/2006
2	Aortic Valve Stenosis (Aortic Stenosis) 01/2009 - 12/2007
2	Embolism (Embolus) 01/2008 - 09/2006
2	Infarction (Infarctions) 01/2008 - 01/2006
1	Fragile X Tremor Ataxia Syndrome 01/2021
1	Spastic Paraplegia Type 4 01/2021
1	Ataxia (Dyssynergia) 01/2021
1	Tremor (Tremors) 01/2021
1	Status Epilepticus (Complex Partial Status Epilepticus) 08/2020
1	Seizures (Absence Seizure) 08/2020
1	Dementia (Dementias) 03/2020
1	Parkinson Disease (Parkinson's Disease) 03/2020
1	alpha-Thalassemia 01/2018
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 04/2014
1	Cardiovascular Diseases (Cardiovascular Disease) 07/2013

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 12/2022 - 01/2006
9	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 02/2019 - 09/2006
6	CalcineurinIBA 01/2011 - 07/2006
4	LigandsIBA 08/2020 - 10/2015
4	Adenosine Triphosphate (ATP)IBA 10/2015 - 06/2011
4	Fas Ligand Protein (Fas Ligand)IBA 01/2011 - 09/2007
4	Calcium-Calmodulin-Dependent Protein KinasesIBA 05/2010 - 09/2006
3	AcidsIBA 04/2022 - 09/2020
3	Fatty Acid Binding Protein 3IBA 08/2020 - 02/2010
3	Sigma-1 ReceptorIBA 09/2018 - 10/2010
3	Fluvoxamine (Luvox)FDA LinkGeneric 01/2014 - 10/2010
3	N-Methylaspartate (NMDA)IBA 01/2011 - 02/2007
3	CalpainIBA 01/2011 - 07/2006
3	Vanadium CompoundsIBA 01/2009 - 03/2008
3	3- (2- (4- (3- chloro- 2- methylphenyl)1- piperazinyl)ethyl)5,6- dimethoxy- 1- (4- imidazolylmethyl)- 1H- indazol dihydrochloride 3.5 hydrateIBA 01/2009 - 01/2006
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2009 - 03/2008
3	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2008 - 09/2006
2	Antiviral Agents (Antivirals)IBA 04/2022 - 01/2022
2	Dehydroepiandrosterone (DHEA)IBA 10/2015 - 12/2011
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2014 - 11/2010
2	Angiotensin IIIBA 01/2014 - 12/2007
2	Nootropic Agents (Nootropics)IBA 04/2012 - 07/2008
2	Haloperidol (Haldol)FDA LinkGeneric 04/2011 - 02/2010
2	Antipsychotic Agents (Antipsychotics)IBA 04/2011 - 10/2009
2	spiro(imidazo- (1,2- a)pyridine- 3,2- indan)- 2(3H)- oneIBA 04/2011 - 07/2008
2	Dopamine (Intropin)FDA LinkGeneric 01/2010 - 10/2009
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 10/2009 - 02/2007
2	3- (2- (4- (3- chloro- 2- methylphenyl)- 1- piperazinyl)ethyl)- 5,6- dimethoxyindazoleIBA 01/2009 - 12/2007
2	Endothelin-1 (Endothelin 1)IBA 01/2009 - 12/2007
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2009 - 03/2008
2	oxovanadium IVIBA 01/2009 - 10/2008
2	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2009 - 09/2007
2	Tyrosine (L-Tyrosine)FDA Link 01/2008 - 01/2006
2	DystrophinIBA 12/2007 - 12/2007
1	Messenger RNA (mRNA)IBA 12/2022
1	5' Untranslated Regions (5' UTR)IBA 12/2022
1	ferrous citrate FDA Link 04/2022
1	Carrier Proteins (Binding Protein)IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2021
1	protoporphyrin IXIBA 01/2021
1	SpastinIBA 01/2021
1	Amino Acids FDA Link 01/2021
1	PorphyrinsIBA 10/2020
1	Diazepam (Valium)FDA LinkGeneric 08/2020
1	Pilocarpine (Ocusert)FDA LinkGeneric 08/2020
1	Pentylenetetrazole (Metrazol)IBA 08/2020
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 03/2020
1	SynucleinsIBA 03/2020
1	Amyloid beta-PeptidesIBA 02/2019
1	T-Type Calcium Channels (T-Type Calcium Channel)IBA 02/2019
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2019
1	SA 4503IBA 09/2018
1	ChromatinIBA 01/2016
1	Adenosine (Adenocard)FDA LinkGeneric 10/2015
1	methyl pyruvateIBA 12/2014
1	Methylphenidate (Ritalin)FDA LinkGeneric 04/2014
1	serum P-component (CIt)IBA 07/2013

Therapy/Procedure

7	Therapeutics 01/2022 - 09/2006
4	Oral Administration 10/2020 - 07/2008
2	Ovariectomy (Oophorectomy) 01/2009 - 12/2007
2	Microspheres (Microsphere) 01/2008 - 09/2006